BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.42%. A quarter ago, it was expected that this rare disease drug developer would post a loss of $0.40 per share when it actually produced a loss of $0.05, delivering a surprise of 87.50%.Over the last four quarters, the ...